Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Acute Respiratory Distress Syndrome (ARDS) (1)
- Anti-infective Agents (1)
- Antibodies (1)
- COVID-19 (1)
- Carcinoma (1)
-
- Chloroquine (1)
- Convalescent Plasma (1)
- Drug Resistance (1)
- Hydroxychloroquine (1)
- Immune Tolerance (1)
- Lopinavir-Ritonavir (1)
- Melanoma (1)
- Microbial (1)
- Monoclonal (1)
- Non-small-cell-lung Cancer (1)
- Pharmacists (1)
- Programmed Cell Death-1 Receptor (1)
- Remdesivir (1)
- Respiratory Tract Infections (1)
- Publication Type
Articles 1 - 3 of 3
Full-Text Articles in Medical Specialties
Coronavirus Disease 2019 (Covid-19), Matthew Dunbar
Coronavirus Disease 2019 (Covid-19), Matthew Dunbar
Pharmacy Student Scholarship
No abstract provided.
Antibiotic Stewardship And Overcoming Antibiotic Resistance In Upper Respiratory Tract Infections, Katherine Elsass, Austin Hilverding, Steve Blake, Brendan Rasor, Steven N. Leonard
Antibiotic Stewardship And Overcoming Antibiotic Resistance In Upper Respiratory Tract Infections, Katherine Elsass, Austin Hilverding, Steve Blake, Brendan Rasor, Steven N. Leonard
Pharmacy and Wellness Review
Antibiotic resistance has rapidly become one of the most significant challenges facing modern health care. Despite widespread public education efforts by the national government and health organizations worldwide, there remains a significant lack of public understanding of antibiotic resistance, how to prevent it and the implications if the science and health care communities fail to find a solution. The Centers for Disease Control and Prevention (CDC) and the American College of Physicians (ACP) recently published updated guidelines for appropriate antibiotic use in upper respiratory tract infections. These guidelines include several key recommendations for acute bronchitis, pharyngitis and acute rhinosinusitis (including …
Programmed Death Pathway Inhibition: Emerging Therapeutic Options For Treatment Of Advanced Or Refractory Cancers, Katherine Elsass, Morgan Homan, Jana Randolph, Brendan Rasor, David Kinder
Programmed Death Pathway Inhibition: Emerging Therapeutic Options For Treatment Of Advanced Or Refractory Cancers, Katherine Elsass, Morgan Homan, Jana Randolph, Brendan Rasor, David Kinder
Pharmacy and Wellness Review
The programmed death-1 (PD-1) pathway has a significant role in the promotion of immune tolerance. The PD-1 receptor ligands are normally expressed on various inactive immune cells. When cancer cells express these ligands, they are able to interact with active T and B lymphocytes to induce this tolerance. Nivolumab and pembrolizumab are two recently approved agents that act to disrupt this binding and facilitate an immune response against cancer cells. Numerous trials, including KEYNOTE-002 and CheckMate 063, have demonstrated the superior safety and efficacy of these drugs in patients with advanced or refractory cancers. Initially approved for the treatment of …